Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
24 studies found for:    Lupus AND Los Angeles | Open Studies
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Abatacept for SLE Arthritis (IM101-330)
Condition: Systemic Lupus Erythematosus Arthritis
Interventions: Drug: abatacept;   Drug: Placebo
2 Recruiting A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
Conditions: Lupus Erythematosus, Systemic;   Lupus Erythematosus;   Fatigue
Interventions: Drug: RAYOS;   Drug: Prednisone
3 Not yet recruiting Study of Anti-Malarials in Incomplete Lupus Erythematosus
Condition: Systemic Lupus Erythematosus Encephalitis
Interventions: Drug: Hydroxychloroquine;   Drug: Placebo Oral Capsule
4 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
5 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir
6 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
7 Not yet recruiting MsciSLE: MSCs in SLE Trial
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Low Dose Mesenchymal Stem Cells (MSCs);   Drug: High Dose Mesenchymal Stem Cells (MSCs);   Drug: Placebo Infusion
8 Recruiting Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
9 Recruiting A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus (SLE)
Interventions: Drug: Placebo;   Drug: Dapirolizumab pegol (DZP)
10 Recruiting Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo
11 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
12 Recruiting Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab
13 Recruiting A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: RSLV-132;   Drug: Placebo
14 Recruiting Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Anifrolumab;   Drug: Placebo
15 Recruiting Rituximab and Belimumab for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
16 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
17 Recruiting Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: BI 655064 dose 1;   Drug: BI 655064 dose 2;   Drug: BI 655064 dose 3;   Drug: Placebo
18 Recruiting Study of IFN-K in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Biological: IFN-Kinoid;   Other: Placebo;   Other: ISA 51
19 Recruiting A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: M2951
20 Recruiting Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Condition: Active Systemic Lupus Erythematosus
Interventions: Biological: Anifrolumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.